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Summary of low-molecular-weight compounds.
* K i values were determined for wild-type HIV-1 protease. [1] 530 GCPII 45 ± 5.7 [1] - To find out whether the aminolytic reaction follows the statistical course, we calculated the composition of the iBodies by analytical methods and compared this to the theoretical composition of the iBodies calculated from the reaction stoichiometry. The values (in red) of the corresponding parameters correlate well, thus proving that the reaction proceeds statistically. The composition of iBodies, as determined by analytical methods (described in the Supporting Information, p. 29). Lines 1-3 represent mass fraction (wt%) of the individual moieties (ATTO488, biotin, targeting ligand). Lines 4-6 represent the number of units (ATTO488, biotin, targeting ligand) per conjugate. Lines 7-9 represent the ratios between the moieties. Ratios were normalized to the lowestincorporated moiety.
Supplementary Table S4
Theoretical composition of iBodies calculated from the reaction stoichiometry
The theoretical composition of iBodies, as calculated from the reaction stoichiometry (described in the Supporting Information, p. 28-33). Lines 1-3 represent the masses of the individual moeities (ATTO488, biotin, targeting ligand) expected to be incorporated into the iBodies. Lines 4-6 represent the moles of each moiety expected to be incorporated into the iBodies. Lines 7-9 represent the ratios between the molar amounts, normalized to the lowest-incorporated moeity. iBodies targeting HIV-1 protease and aspartic proteases (pepsin). a) Affinity isolation of HIV-1 protease from the HIV-1 protease-spiked LNCaP cell lysate using iBody 2 and iBody 3; iBody 6 lacking the targeting ligand was used as a negative control. b) Affinity isolation of pepsin from the pepsin-spiked cell lysate using iBody 3; as a negative control, iBody 6 was used.
Supplementary methods

HPLC-based GCPII inhibition assay
The inhibitory effects of all inhibitors and iBodies targeting GCPII were tested using an HPLC-based assay with recombinant extracellular GCPII, as described previously [1] . The data were processed and IC 50 values were obtained using GraFit v. 5.0.11 (Erithacus Software Ltd.) .
From the kinetic parameters of pteroyl-di-L-glutamate cleavage and by assuming a competitive mode of inhibition, the K i value was calculated using the Cheng-Prusoff equation [3] . Measurements were performed in duplicate; the Ki values are presented as the mean ± standard deviation.
Pull-down/immunoprecipitation of GCPII from LNCaP lysate
LNCaP cells endogenously expressing GCPII were lysed by sonication in 50 mM Tris- To compare iBodies with antibodies, an analogous immunoprecipitation experiment with the monoclonal antibody J591 [4] was performed. First, 200 μl of 30 nM J591 was bound to 30 μl Protein G Sepharose (GE Healthcare), washed with TBST, and mixed with LNCaP lysate. After incubation, the resin was washed with TBST, and proteins were eluted with reducing SDS sample buffer and heating.
Isolated GCPII was visualized on Western blot using mAb GCP-04, followed by goat anti-mouse secondary antibody conjugated with horseradish peroxidase. 10 μl of the sample was loaded into each lane.
Quantitative detection of GCPII using ELISA
When iBody 1 was used in place of the detecting antibody, a 96-well Maxisorb plate (Nunc) was coated with the GCPII-specific mouse antibody 2G7 [5] in borate buffer (500 ng/well; 1 h at RT). The surface was blocked with 1.1 % (w/v) casein solution in TBS (Casein Buffer 20X-4X Concentrate, SDT). Afterwards, recombinant extracellular GCPII in TBST was added (ranging from 0.5 pg -1 ng/well) and, after washing with TBST (3×200 μl), 500 pM iBody 1 or biotinylated anti-GCPII mAb J591 in TBST was added to bind GCPII.
After washing out the unbound conjugate (3×200 μl TBST), NeutrAvidin conjugated with horseradish peroxidase was added (50 ng/well; Thermo Scientific), followed by a final TBST wash (5×200 μl) and measurement of 4-iodophenol-enhanced luminol chemiluminescence on a Tecan Infinite M1000 PRO spectrophotometric reader. Measurement of each sample was performed in triplicate; values are presented as the mean ± standard deviation.
Confocal microscopy of fluorescently labeled cells
LNCaP After two days, iBody solution was added to the media to a final concentration of 10 nM. If desirable, 2-(phosphonomethyl)pentanedioic acid (2-PMPA) was added to a final concentration of 500 nM. As a control, fluorescently labeled anti-GCPII monoclonal antibody 2G7 [5] (2G7-ATTO488) was added to a final concentration of 100 nM. The cells were incubated in the presence of iBodies for 2 h at 37 °C. Then, the media were removed, a 0.5 μg/ml solution of Hoechst Stain Solution H34580 (Sigma) in PBS was added, and cells were incubated for 10 min at 37 °C to stain cell nuclei. Finally, the cells were washed twice with 500 μl PBS. 
Quantification of iBody binding to GCPII by surface plasmon resonance (SPR)
All SPR measurements were performed at 25 °C according to a previously described protocol [1, 6] . In a typical experiment, a 7:3 mixture of HS-(CH 2 ) 11 -PEG 4 -OH and HS-(CH 2 ) 11 -PEG 6 -O-CH 2 -COOH alkanethiols (Prochimia) at a final concentration of 0.2 mM was incubated with an SPR chip (provided by the Institute of Photonics and Electronics, Prague)
for 1 h at 37 °C. The chip was then washed with UV ethanol and deionized water and dried with a flow of nitrogen gas. Finally, the chip was mounted to the prism on the SPR sensor.
Activation of carboxylic terminal groups on the sensor surface was performed in situ by injecting a 1:1 mixture of 11.51 mg/ml N-hydroxysuccinimide (NHS) and 76.68 mg/mL 1-
(Biacore) for 5 min at a flow rate of 20 µl/min. The next part of the experiment was performed at a flow rate of 30 µl/min. Then, a mixture of the antibody D2B [7] , which recognizes native GCPII (20 ng/µl), and BSA (20 ng/µl) in 10 mM sodium acetate, pH 5.0, was loaded for 8 min. Next, a high ionic strength solution (PBS with 0.5 M NaCl) was used to wash out noncovalently bound molecules, followed by addition of 1 M ethanolamine (SigmaAldrich) for deactivation of residual activated carboxylic groups.
An 8 ng/µl solution of recombinant extracellular GCPII in TBS (Avi-GCPII [8] ) was used for Avi-GCPII immobilization onto the D2B/BSA layer on the golden chip to saturate all binding sites. Finally, at a flow rate of 60 µl/min, 4 different concentrations (1, 2, 4 , and 8 nM) of iBody 1 in TBS were applied for approximately 10 min (association), followed by injection of TBS alone (dissociation).
Kinetic curves of binding were exported and subsequently fitted using the One-ToOne interaction model in TraceDrawer v.1.5 (Ridgeview Instruments AB) to obtain k on and k off parameters.
SDS-PAGE and Western blotting
Protein samples were resolved by SDS-PAGE, and gels were electroblotted onto a nitrocellulose or PVDF membrane (wet blotting: 100 V/1 h). Membranes were blocked with 1.1 % (w/v) casein solution in PBS (Casein Buffer 20X-4X Concentrate, SDT) at room temperature for 1 h. Afterwards, the blots were incubated with the primary antibody GCP- [9] at 4 °C for 12 h (200 ng/ml; diluted in 0.55 % casein solution), washed three times with PBS containing 0.05 % Tween 20 (PBST), and incubated with goat anti-mouse secondary antibody conjugated with horseradish peroxidase (Thermo Scientific; diluted 1:25,000 in 0.55 % casein solution). For polyhistidine sequence (His-tag) detection, either anti-polyhistidine-peroxidase antibody (Sigma Aldrich, #A7058-1VL) (1:2,000 dilution in PBST) or iBody 4 (5 nM in PBST, loaded with nickel ions) followed by NeutrAvidin-HRP conjugate (dilution 1:2,000 in PBST) was used.
Finally, the blots were washed three times with PBST to remove free antibodies, and
SuperSignal West Dura/Femto Chemiluminescent Substrate (Thermo Scientific) was applied.
Chemiluminiscence was captured with a ChemiDoc-It TM 600 Imaging System (UVP).
Preparation of a fluorescently labeled anti-GCPII monoclonal antibody 2G7 (2G7-
ATTO488)
An antibody against human native GCPII (2G7 [5] ) was labeled with a fluorophore ATTO488 using ATTO488 NHS ester (Sigma Aldrich, #41698). First, 77 μl of a 2.5 mg/ml solution of the antibody 2G7 in PBS was mixed with 8.6 μl of 100 mM bicarbonate buffer, pH 8.3. ATTO488 NHS ester was dissolved in dry DMSO at 10 mg/ml. Afterwards, 1 μl of the ATTO488 NHS ester solution was mixed with the antibody solution and incubated for 1 h at room temperature. Finally, the fluorophore-antibody conjugate (2G7-ATTO488) was separated from the free fluorophore by gel permeation chromatography using Sephadex G-25
column. Fractions containing 2G7-ATTO488 were pooled and concentrated using Amicon Ultra 30 kDa centrifugal filter (Millipore).
Flow cytometry
PC3 and LNCaP cell lines were grown on a 100 mm dish to 90 % confluence in DMEM and RPMI medium, respectively; both supplemented with 10 % FBS and 4 mM Lglutamine. The medium was removed, and cells were rinsed with PBS and subsequently incubated in 1.5 ml trypsin/EDTA solution for 3 min to release adherent cells from the dish surface. Cells were resuspended and transferred into 8 ml of DMEM or RPMI medium, centrifuged at 250×g for 2 min, and washed with 5 ml PBS. Then, 500 μl of 10 % fetal bovine 
Inhibition of HIV-1 protease activity with inhibitors and iBodies
The inhibition analyses were performed by spectrophotometric assay using the chromogenic peptide substrate KARVNle*NphEANle-NH 2 as previously described [10] .
The 1 ml reaction mixture contained 100 mM sodium acetate, 300 mM NaCl, pH 4.7, 6.8 pmol of HIV-1 protease [10] and inhibitor in concentrations ranging between 2 and 130 nM.
Substrate was added to a final concentration of 16 μM. Afterwards, the hydrolysis of substrate was followed as a decrease in absorbance at 305 nm using a UNICAM UV500 UV−VIS spectrophotometer (Thermo, Cambridge, MA). The data were analyzed using the equation for competitive inhibition according to Williams and Morrison [11] . The mechanism of inhibition was determined by analysis of Lineweaver-Burk plots.
Pull-down of HIV-1 protease from spiked LNCaP lysate
LNCaP cells grown on two 100 mm Petri dishes were lysed by sonication (3×5 min, in water bath) in 2 ml of 50 mM Tris-HCl, 150 mM NaCl, 1 % Tween 20, pH 7.4.
First, 200 nM iBody 2 or 3 in 20 mM Tris-HCl, 150 mM NaCl, 0.1 % Tween 20, pH 7.4, was bound to 30 μl Streptavidin Agarose Ultra Performance (Solulink) at room temperature for 1 h. iBody 6, which lacks the targeting ligand, was used as a negative control.
To block unoccupied biotin binding sites, the resin was incubated with 1 ml of 2 mM biotin, 20 mM Tris-HCl, 150 mM NaCl, pH 7.4. Then, the resin was washed three times with 1 ml of 100 mM sodium acetate, 300 mM NaCl, 0.1 % Tween 20, pH 4.7. The washed resin was mixed with 200 μl of LNCaP cell lysate spiked with HIV-1 protease [10] (12 ng/μl, total protein concentration 1 mg/ml) in 100 mM sodium acetate, 300 mM NaCl, 0.1 % Tween 20, pH 4.7, and incubated for 30 min at room temperature. The resin was washed four times with 1 ml of 100 mM sodium acetate, 300 mM NaCl, 0.1 % Tween 20, pH 4.7. Finally, bound HIV-1 protease was eluted from Streptavidin Agarose by adding 30 μl reducing SDS sample buffer and heating to 98 °C for 10 min. Ten microliters of the samples was loaded onto the gel.
Pull-down of pepsin from spiked LNCaP lysate
The experiment was performed analogously to the above described pull-down of HIV- 
Quantification of iBody binding to Ddi1-HisTag by surface plasmon resonance (SPR)
The experiment was performed analogously to quantitation of iBody 1 binding to GCPII.
Activation of carboxylic terminal groups on the sensor surface was performed in situ by injecting a 1:1 mixture of 11.51 mg/ml N-hydroxysuccinimide (NHS) and 76.68 mg/mL 1- 
Inductively coupled plasma atomic emission spectroscopy (ICP-OES)
The ICP-OES measurements were performed with the SPECTRO ARCOS optical emission spectrometer (SPECTRO Analytical Instruments, Kleve, Germany) with radial plasma observation. The SPECTRO ARCOS features a Paschen-Runge spectrometer mount; the wavelength range between 130 and 770 nm can be analyzed simultaneously. An aircooled ICP-generator, based on a free-running 27.12 MHz system, is installed. For sample introduction, a Modified-Lichte nebulizer with a cyclonic spray chamber was used.
For calibration, commercially available Br and S standard solutions (Analytika) were used. 0.5 % (v/v) Triton X-100 and 2 % HNO 3 solution were used for organic matrix matching strategy and improvement of LOD. Before analysis, the analyzed polymer conjugate solutions were diluted with 0.5 % Triton X-100 solution, as well as all calibration standard solutions. All used chemicals were suprapur quality. All calibrations and sample solutions 
Synthesis of low-molecular-weight compounds
All chemicals were purchased from Sigma-Aldrich, unless stated otherwise. All inhibitors tested in the biological assays were purified using preparative scale HPLC Waters Delta 600 (flow rate 7 ml/min, gradient shown for each compound -including RT), with column Waters SunFire C18 OBD Prep Column, 5 µm, 19×150 mm. The purity of compounds was tested on analytical Jasco PU-1580 HPLC (flow rate 1 ml/min, invariable 
Synthesis of compound 1
Compound 1 was synthesized according to the scheme depicted below:
Di-tert-butyl 2-(3-(6-((4-bromobenzyl)amino)-1-(tert-butoxy)-1-oxohexan-2-yl)ureido)pentanedioate, compound 102: 300 mg (0.615 mmol, 1.0 eq) of di-tert-butyl 2-(3-(6-amino-1-(tert-butoxy)-1-oxohexan-2-yl)ureido)pentanedioate (compound 101, prepared as described in Murelli et al. [12] ) and 120 mg (0.646 mmol, 1.05 eq) of 4-bromobenzaldehyde was dissolved in 5 ml of methanol in a round-bottom flask. 50 µl of glacial acetic acid was added and, upon fast stirring, 120 mg (1.85 mmol, 3.0 eq) of sodium cyanoborohydride was added in one portion. After 12 hours, the reaction mixture was quenched by addition of 10 ml of water. The reaction mixture was further diluted after 10 minutes by 50 ml of water and was extracted 3 times by EtOAc (3×25 ml). The organic phase was dried and evaporated and Compound 1: 28,30-tricarboxy-18,26-dioxo-3,6,9,12,15-pentaoxa-19,25 ,27-triazatriacontan-1-aminium 2,2,2-trifluoroacetate, compound 1: 137 mg (0.34 mmol, 1.1 eq) of Boc-NH-PEG 5 -CH 2 CH 2 COOH (PurePEG, #432705) was dissolved in 1 ml of DMF along with 1222 mg (0.38 mmol, 1.25 eq) of TBTU. 132 µl (0.76 mmol, 2.5 eq)
of DIEA were added in one portion and the reaction mixture was left stirring for 10 minutes. 
Synthesis of compound 2
Compound 2, based on a commercially available HIV protease inhibitor drug ritonavir (RTV), was synthesized according to the below depicted scheme:
Isolation of ritonavir (RTV) from commercially available capsules: RTV is suspended in capsules in an oily mixture of rather non-polar compounds. 50 tablets (100 mg RTV each)
were cut open and the oily substance was squeezed out into a round-bottom shaped 2 l flask.
200 ml of hexan was added along with 500 ml of diethyl ether. The resulting suspension was triturated and sonicated for 3 hours until all oil turned into a white precipitate. This precipitate was filtred and again triturated/sonicated in pure diethyl ether, after which the pure RTV was filtred. 3.6 g of RTV was obtained (isolation yield 72 %). The purity of RTV was determined by HPLC and was well above 99 % (analytical HPLC R T = 23.7 min).
Compound 103 Partial hydrolysis of ritonavir (RTV), thiazol-5-ylmethyl ((2S,3S,5S)-5-amino-3-hydroxy-1,6-diphenylhexan-2-yl)carbamate, compound 103: 1.00 g of RTV was dissolved in 50 ml of dioxan in a bottom-round flask. 50 ml of concentrated hydrochloric acid was added and the resulting mixture was stirred at 65 °C for 20 hours (note that different temperature and/or time lead to different cleavage products). After 20 hours the mixture was let cool down to RT. The reaction mixture was neutralized by addition of K 2 CO 3 until the resulting mixture showed basic pH. The solvents were concentrated using rotary evaporater to roughly 50 ml and diluted by 150 ml of water and washed 3 times by 100 ml of EtOAc. The water phase was discarded and organic phase was dried and evaporated. 885 mg of crude product was obtained and was used in the next step without further purification (purity roughly 70 % -HPLC determination). For spectral determination, 50 mg was purified using preparative HPLC Compound 104 Thiazol - (5S,6S,8S,11S) -5,8-dibenzyl-6-hydroxy-11-isopropyl-3,10,13,22-tetraoxo-1-(thiazol-5-yl)-2,15,18,24,27-pentaoxa-4,9,12,21-tetraazanonacosan-29- isobutyl-19,22-diisopropyl-30,35-dimethyl-8,17,20,23,28,31-hexaoxo-3,6,12,15-tetraoxa-9,18,21,24,29 ,32-hexaazahexatriacontan-1-aminium, compound 3: The pepstatin inhibitor was synthesized by standard amino-Fmoc synthesis on solid phase, using 2-chlortrityl chloride resin (Iris-Biotech). The first amino acid (Fmoc-Sta-OH) was attached to the solid phase according to the manufacturer`s instructions: the resin was left to react with Fmoc-Sta-OH (0.6 eq to resin substitution) in presence of 4 equivalents of DIEA for 2 hours in DCM.
The remaining reactive residues were quenched with mixture of DCM/MeOH/DIEA (17:2:1) for 15 minutes. All other amino acids and the linker Boc-O2Oc-O2Oc-OH (Iris-Biotech, #BAA1485) were added using HOBt/DIC method. The peptide was then cleaved from the solid phase using 95 % TFA and the crude product was purified using preparative HPLC (gradient: 10-50 % ACN in 40 minutes. R T = 26 min). Analytical HPLC R T = 16.5 min. 9 , compound 105: The synthesis was performed as described previously [13] with an only minor variation in one step (for the reaction between 3 monomers of NTA and lysine tricarboxylic acid derivative TSTU was used as an activation reagent, instead of NHS/DCC, because it gave much better yields).
HRMS (ESI-
)
Compound 4
Compound 105 (52 mg, 38 µmol, 1.0 eq, purified by HPLC before this step) was dissolved in 1 ml of DMF and 15 mg (38 µmol, 1.0 eq) of the linker Boc-O2Oc-O2Oc-OH (Iris-Biotech, #BAA1485) was added in one portion. To this reaction mixture was added 16 mg (76 µmol, 2.0 eq) of DCC and the reaction was left for 24 hours stirring at room temperature. The solvents were evaporated and the crude mixture was treated with 1 ml of pure TFA, and the reaction mixture was alternately stirred and sonicated for 3 hours. 
Synthesis of monomers, polymer precursors and polymer conjugates
Synthesis of HPMA copolymer conjugates (iBodies)
Generally, the HPMA copolymer conjugates (iBodies 1-6) were prepared by reaction of the polymer precursor poly(HPMA-co-Ma-ß-Ala-TT) with the affinity anchor N-(2-aminoethyl)biotinamide hydrobromide (biotin-NH 2 ) or with a combination of fluorophore (ATTO488-amine), affinity anchor (biotin-NH 2 ), and targeting ligand (compounds 1-4). To achieve statistical representation of all three ligands in the conjugate, the aminolysis of the statistical TT groups-containing polymer precursor [14] with the -CH 2 CH 2 NH 2 group-bearing compounds was performed simultaneously in one step. Yield of the aminolytic reaction was approximately 60-70 % for all three compounds. The compounds were dissolved in DMSO,
and N,N-diisopropylethylamine (DIPEA) was added. The reaction mixture was stirred at room temperature, and the unreacted thiazolidine-2-thione groups were quenched with 1-aminopropan-2-ol. Polymer conjugates were isolated by precipitation into an acetone:diethyl ether mixture (3:1), filtered off, washed with acetone and diethyl ether, and dried in vacuo.
Finally, the conjugates were purified on a Sephadex LH-20 chromatography column with methanol as the mobile phase, precipitated into diethyl ether, filtered off, and dried in vacuo.
The synthesis of all iBodies, polymer precursors and monomers is described in more detail below.
Determination of the composition (i.e. the number of each moiety) of the iBodies
Content of ATTO-488 was determined using spectrophotometry (ε 502nm = 90,000 l.mol -1 .cm -1 , water). For polymer conjugates containing only biotin and/or targeting group, content of biotin was determined spectrophotometrically using HABA/avidin reagent according to manufacturer's instruction (Sigma-Aldrich). For polymer conjugates containing both biotin and ATTO488, content of biotin was determined using inductively coupled plasma atomic emission spectroscopy (ICP-OES; sulphur detection), since HABA/avidin method was not applicable due to ATTO488 absorption at 500 nm. Content of targeting groups (compounds 1-4) was determined in the sample hydrolyzate (6N-HCl, 115 °C, 16 h) using HPLC-based o-phtaldialdehyde pre-column derivatization method on the Chromolith C18 column with a fluorescence detector (Ex. 229 nm, Em. 450 nm). As standards, the corresponding low-molecular-weight inhibitors were hydrolyzed and derivatized in the same way.
Determination of molecular weight of polymer conjugates
The weight-average molecular weights (M w ), number average molecular weights (M n ), and dispersities (Ð) of the polymer precursor and conjugates were determined using HPLC Shimadzu system equipped with a UV detector, an Optilab ® rEX differential refractometer and multi-angle light scattering DAWN ® 8™ (Wyatt Technology, USA) detector and sizeexclusion chromatography TSKgel G4000SW column. The M w , M n and Đ were calculated using the Astra V software. The refractive index increment dn/dc = 0.167 ml/g was used for
calculation. For these experiments, a 20 % 300 mM acetate:80 % methanol (v/v) buffer was used. The flow rate was 0.5 mL/min. The data are summarized in Table S2 .
Synthesis of monomers
N-(2-Hydroxypropyl)methacrylamide (HPMA) was synthesized by reaction of methacryloyl chloride with 1-aminopropan-2-ol in dichloromethane in the presence of sodium carbonate [15] .
3-(3-Methacrylamidopropanoyl)thiazolidine-2-thione (Ma-ß-Ala-TT) was prepared by reaction of 3-methacrylamidopropanoic acid and 4,5-dihydrothiazole-2-thiol (H-TT) (4.37 g,
